Harrow, Inc. Deferred Federal Income Tax Expense (Benefit)
Harrow, Inc. (HROW) reported Deferred Federal Income Tax Expense (Benefit) of $871.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2023-03-23
- Harrow, Inc. deferred federal income tax expense (benefit) for the quarter ending 2012-12-31 was $0.00.
- Harrow, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was $871.00K.
- Harrow, Inc. deferred federal income tax expense (benefit) for fiscal 2021 was -$425.00K.
- Harrow, Inc. deferred federal income tax expense (benefit) for fiscal 2020 was -$771.00K, a 215.25% decline from fiscal 2019.
- Harrow, Inc. deferred federal income tax expense (benefit) for fiscal 2019 was $669.00K, a 79.69% decline from fiscal 2018.
| Period end | Deferred Federal Income Tax Expense (Benefit) 3 month | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|
| 2022-12-31 | $871.00K 10-K · filed 2023-03-23 | ||
| 2021-12-31 | -$425.00K 10-K · filed 2023-03-23 | ||
| 2020-12-31 | -$771.00K 10-K · filed 2022-03-10 | ||
| 2019-12-31 | $669.00K 10-K · filed 2021-03-08 | ||
| 2018-12-31 | $3.29M 10-K · filed 2020-03-13 | ||
| 2017-12-31 | $6.47M 10-K · filed 2019-03-12 | ||
| 2016-12-31 | -$5.62M 10-K · filed 2018-03-08 | $19.85M 10-K · filed 2017-03-21 | |
| 2015-12-31 | $14.04M 10-K · filed 2017-03-21 | $3.14M 10-K · filed 2016-03-23 | |
| 2014-12-31 | $3.02M 10-K · filed 2016-03-23 | $11.08M 10-K · filed 2015-03-12 | |
| 2013-12-31 | $8.08M 10-K · filed 2015-03-12 | ||
| 2012-12-31 | $0.00 10-K · filed 2013-03-18 | $6.18M 10-K · filed 2014-03-28 | |
| 2011-12-31 | $0.00 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |